Subscribe to Newsletter
Inside the Lab Genetics and epigenetics, Biochemistry and molecular biology, Technology and innovation, Regulation and standards

Meddling with Nature

Human germline genome editing (hGGE) has great medical potential, especially in preventing heritable disorders; it can delete, add to, or even replace DNA sequences that are expressed in cells and passed onto the next generation. CRISPR-Cas9, the most widely used genome editing tool, targets specific DNA sequences and cuts them using the Cas9 enzyme, allowing for changes before the cell repairs the cut.

However, a new report from the UK Parliamentary Office of Science and Technology has urged caution, calling for a full review of the potential clinical effectiveness, cost-effectiveness, and risks and benefits of hGGE before deeming it safe (1). For those with serious monogenic disorders, such as cystic fibrosis, hGGE could ensure that their children won’t suffer from the same condition. But for now, at least in the UK, the Human Fertilization and Embryology Act 1990 prohibits implanting embryos with altered germline DNA inside a woman. The Human Fertilization and Embryology Authority can award licenses for research – but only for projects that involve human embryos outside the body. Safety and ethical concerns have arisen around the world; in China, for example, one scientist claimed to have edited the genome of embryos that resulted in the birth of twin girls (2).

The new report calls for further advancements before hGGE could be considered safe for clinical use.

Before hGGE can be adopted in the clinic, a number of safety issues loom large. The main concerns involve edits being made at incorrect DNA sites, or potential unintended consequences of correct edits. There’s also the possibility that a cell repairs cut DNA in an unanticipated way, or that the edited DNA sequence is absent in some cells. Genome editing techniques continue to improve – but the new report calls for further advancements before hGGE could be considered safe for clinical use.

With so many unanswered questions surrounding hGGE, some scientists want a moratorium on clinical heritable genome editing until a universal framework is established (3). Several international initiatives have already tried to address the issue – and, in 2019, the WHO launched a global registry for human genome editing that aims to track all research and make recommendations on appropriate legislation (4). Watch this space…

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. UK Parliament Post Note, “Human Germline Genome Editing” (2020). Available at:
  2. Science, “Did CRISPR help—or harm—the first-ever gene-edited babies?” (2019). Available at:
  3. ES Lander et al., “Adopt a moratorium on heritable genome editing”, Nature, 567, 165 (2018). PMID: 30867611.
  4. World Health Organization, “A global observatory for gene editing” (2019). Available at:
About the Author
Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine